Last month, I consulted with two psychiatrists and a nurse practitioner who currently prescribe medications for some of my clients. I reached out to share the taper plans I developed for them—integrating the Brainbow Blueprint lifestyle with hyperbolic tapering, a method designed to help patients discontinue medications safely and successfully.
To my surprise, none of them had ever heard of hyperbolic tapering. These are clinicians prescribing psychotropic medications, yet they don’t know how to guide someone through the process of coming off them.
Our medical system teaches practitioners how to prescribe, but not how to deprescribe. So often, they don’t know how to help their patients, who then fail and are told, “You will be on meds forever.” Not so! Knowing how to support patients through withdrawal is essential for their success. With rare exception, everyone can taper.
What Is Hyperbolic Tapering?
Hyperbolic tapering is a slow, non-linear method for reducing psychiatric medications. It recognizes that the brain doesn’t respond to dose changes in a straight line—small reductions at lower doses can have disproportionately large effects on receptor activity.
Instead of cutting doses by equal percentages, hyperbolic tapering follows a curved pattern of progressively smaller reductions as the taper advances. This prevents abrupt neurochemical changes that can trigger withdrawal symptoms and destabilization.
In other words, the lower the dose, the smaller each subsequent step. This gentle, evidence-based, curved approach gives the brain time to recalibrate and restore equilibrium, reducing the likelihood of rebound anxiety, insomnia, or mood instability.
What Psychotropic Medications Require Hyperbolic Tapering?
Antidepressants
- SSRIs: paroxetine, sertraline, citalopram, escitalopram, fluoxetine
- SNRIs: venlafaxine, duloxetine, desvenlafaxine
- TCAs and MAOIs
A 2023 cohort study of over 600 patients who tapered antidepressants using a hyperbolic method found that slower, smaller dose reductions were strongly associated with fewer withdrawal complaints and higher tapering success rates (van Os & Groot, 2023).
Antipsychotics
- risperidone, olanzapine, quetiapine, aripiprazole, haloperidol
Emerging evidence suggests that a hyperbolic approach benefits antipsychotic discontinuation. In a 2021 review, researchers proposed that gradual, logarithmic dose reductions—about 25% every six months—resulted in fewer relapses than standard tapering or abrupt discontinuation (Horowitz et al., 2021).
Benzodiazepines
- diazepam, clonazepam, lorazepam, alprazolam
The latest deprescribing guidelines reinforce this. A multidisciplinary expert panel on benzodiazepine receptor agonists emphasized micro-tapering and hyperbolic reductions as best practice for minimizing withdrawal and supporting long-term stability (Brandt et al., 2025).
What Medications Usually Do Not Require Hyperbolic Tapering?
- Lithium
- Stimulants: methylphenidate, amphetamine
- Buspirone
- Anticonvulsants used as mood stabilizers: valproate, carbamazepine, lamotrigine
Integrating Lifestyle Medicine and Hyperbolic Tapering
Medication tapering is not just a mathematical process; it’s a physiological and psychological transition.
That’s why it’s essential to combine it with lifestyle changes that support each phase of the process:
- Bioindividual Nutrition
- Gentle movement and breath-centered practices
- Deep, consistent sleep
- Detoxifying support and targeted supplementation
When these practices accompany a well-structured taper plan, we are helping our clients get on the path to success.
Read the story of my client Noah, an example of how combining an integrative approach to tapering with lifestyle and an individualized self-care routine can lead to steady progress and long-term wellness.
Moving Forward
Prescribers don’t need to become tapering specialists to make a difference—they simply need to understand that the process of coming off medication is as complex as starting it.
When we bring together the science of hyperbolic tapering with the supportive practices of lifestyle medicine, we help patients transition safely, gently, and with greater confidence in their bodies’ capacity to heal.
The more we collaborate—clinicians, patients, and integrative practitioners—the more compassionate and effective this process becomes.
If you’d like to explore how this approach works in practice and access tools for guiding patients through safe medication reduction, you can visit my page, Deprescribing and Tapering Antidepressants, Anti-Psychotics, Anxiolytics, and Other Psychotropic Medications.
References
Brandt, J., Lader, M., Soyka, M., & O’Brien, C. (2025). Benzodiazepine receptor agonist deprescribing: Principles for harm minimization and discontinuation. Journal of General Internal Medicine. https://www.researchgate.net/publication/393402417
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021). A method for tapering antipsychotic treatment that may improve outcomes. Schizophrenia Bulletin, 47(4), 1116–1129. https://pmc.ncbi.nlm.nih.gov/articles/PMC8266572/van Os, J., & Groot, P. C. (2023). Outcomes of hyperbolic tapering of antidepressants.Therapeutic Advances in Psychopharmacology, 13, 204512532311703. https://pubmed.ncbi.nlm.nih.gov/37200818/
She served as a Fulbright scholar on traditional medicine, a Clinical Fellow at Harvard Medical School, and a National Institutes of Health-funded research scientist in mind/body medicine.
- Hyperbolic Tapering: What Every Clinician Should Know - November 3, 2025
- First Steps in Understanding Cognitive Decline: Causes, Screening, and Prevention - October 13, 2025
- GLP-1 Agonists: A New Frontier in Brain and Metabolic Health - September 17, 2025
Are You Ready to Advance Your Career?
If you want to advance your career in integrative medicine, explore my courses and certifications.
